Tau-441 (2N4R) P301S Mutant Pre-formed Fibrils: ATTO 488
Product Sizes
100 ug
SPR-329-A488-100UG
2 x 100 ug
SPR-329-A488-2X100UG
5 x 100 ug
SPR-329-A488-5X100UG
About this Product
- SKU:
- SPR-329-A488
- Additional Names:
- Tau-441, Tau-F, Tau 441, 2N4R, MAPT, TAU, MTBT1, MTBT2, MAPTL, PPND, PPP1R103, FTDP-17, PHF-Tau, Paired Helical Filament-Tau, Neurofibrillary Tangle, NFTs, intracellular neurofibrillary tangles, Tau aggregates, Tau inclusions, G Protein Beta1/Gamma2 Subunit-Interacting Factor 1, ATTO 488 conjugated Tau, ATTO labelled Tau fibrils, Tau PFFs
- Application:
- Cell-based/Functional Assay, SDS-PAGE, Western Blot
- Buffer:
- PBS pH7.4, 0.09% Azide
- CE/IVD:
- RUO
- Conjugate:
- ATTO 488
- Extra Details:
- Tau-441, the longest isoform of the microtubule-associated protein tau (MAPT), contains two N-terminal inserts and four microtubule-binding repeats (2N4R), playing a critical role in stabilizing neuronal microtubules and maintaining axonal transport. The P301S mutation, a proline-to-serine substitution at residue 301, is linked to familial tauopathies and significantly enhances tau's aggregation propensity. Pre-formed fibrils (PFFs) generated from Tau-441 P301S mutant proteins replicate the structural and pathological features of tau aggregates found in neurodegenerative diseases such as frontotemporal dementia and Alzheimer's disease. These fibrils act as potent seeds, inducing the misfolding and aggregation of endogenous tau in a prion-like manner. This seeding mechanism drives the spread of tau pathology across neural circuits, leading to synaptic dysfunction, neuroinflammation, and progressive neuronal loss. Experimental models employing P301S mutant PFFs have demonstrated their ability to initiate early tau pathology, including the formation of neurofibrillary tangles and tau-positive inclusions. These models are instrumental in dissecting the molecular mechanisms of tau propagation and identifying therapeutic targets. Tau-441 P301S mutant PFFs are essential tools for studying the dynamics of tau aggregation and its role in neurodegeneration. Their use in preclinical research accelerates the development of disease-modifying therapies aimed at halting tau spread, enhancing clearance, and restoring neuronal function in tauopathies.
- Immunogen:
- Tau-441 (2N4R) P301S PFFs
- Purity:
- >95%
- Purification:
- Ion Exchange
- Sequence:
- MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEDGSEEPG SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTEIPEG TTAEEAGIGD TPSLEDEAAG HVTQARMVSK SKDGTGSDDK KAKGADGKTK IATPRGAAPP GQKGQANATR IPAKTPPAPK TPPSSGEPPK SGDRSGYSSP GSPGTPGSRS RTPSLPTPPT REPKKVAVVR TPPKSPSSAK SRLQTAPVPM PDLKNVKSKI GSTENLKHQP GGGKVQIINK KLDLSNVQSK CGSKDNIKHVSGGGSVQIVY KPVDLSKVTS KCGSLGNIHH KPGGGQVEVK SEKLDFKDRV QSKIGSLDNI THVPGGGNKK IETHKLTFRE NAKAKTDHGA EIVYKSPVVS GDTSPRHLSN VSSTGSIDMV DSPQLATLAD EVSASLAKQG L
- Shipping Conditions:
- Dry Ice
- Storage Conditions:
- -70[o]C
- Supplier:
- StressMarq Biosciences
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Conjugated Protein
- Manufacturer's Data Sheet:https://www.stressmarq.com/products/protein/tau-protein-spr-329-a488/
